Stocks News

LAST PRICE
256.1700
TODAY'S CHANGE (%)
Trending Down-3.0000 (-1.1575%)

Bid / Lots
256.6900/ 1
Ask / Lots
259.6100/ 1
Open / Previous Close
260.0000 / 259.1700
Day Range
Low 252.2700
High 262.2500
52 Week Range
Low 119.7604
High 299.9800
Volume
292,365
average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Aug 8, 2024
- DJ Madrigal Pharmaceuticals Is Maintained at Buy by Citigroup, from 3:32PM ET on Thursday Aug 08, 2024 by Dow Jones
  3:32PM ET on Thursday Aug 08, 2024 by Dow Jones
  Companies Mentioned: MDGL
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/MDGL/analyst-ratings
  
  (END) Dow Jones Newswires
  
  August 08, 2024 15:32 ET (19:32 GMT)
- DJ Madrigal Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group, from 9:19AM ET on Thursday Aug 08, 2024 by Dow Jones
  9:19AM ET on Thursday Aug 08, 2024 by Dow Jones
  Companies Mentioned: MDGL
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/MDGL/analyst-ratings
  
  (END) Dow Jones Newswires
  
  August 08, 2024 09:19 ET (13:19 GMT)
- B. Riley Adjusts Price Target on Madrigal Pharmaceuticals to $194 From $200, Maintains Neutral Rating, from 8:43AM ET on Thursday Aug 08, 2024 by MT Newswires
  8:43AM ET on Thursday Aug 08, 2024 by MT Newswires
  Companies Mentioned: MDGL
  08:43 AM EDT, 08/08/2024 (MT Newswires) -- Madrigal Pharmaceuticals (MDGL) has an average rating of outperform and price targets ranging from $150 to $507, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and econom...
Aug 7, 2024
- Madrigal Pharmaceuticals Reports Q2 Revenue as Loss Widens; Shares Gain Pre-Bell, from 8:14AM ET on Wednesday Aug 07, 2024 by MT Newswires
  8:14AM ET on Wednesday Aug 07, 2024 by MT Newswires
  Companies Mentioned: MDGL
  08:14 AM EDT, 08/07/2024 (MT Newswires) -- Madrigal Pharmaceuticals (MDGL) reported a Q2 net loss Wednesday of $7.10 per diluted share, widening from a loss of $4.69 a year earlier. Analysts polled by Capital IQ expected a loss of $7.61. Total reven...
- -- Earnings Flash (MDGL) MADRIGAL PHARMACEUTICALS Posts Q2 Loss $-7.10, vs. Street Est of $-7.61, from 7:07AM ET on Wednesday Aug 07, 2024 by MT Newswires
  7:07AM ET on Wednesday Aug 07, 2024 by MT Newswires
  Companies Mentioned: MDGL
  07:07 AM EDT, 08/07/2024 (MT Newswires) -- ...

Today
- Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 7 hours ago by PR Newswire
  7 hours ago by PR Newswire
  Companies Mentioned: RNA
- Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 7 hours ago by Dow Jones
  7 hours ago by Dow Jones
  Companies Mentioned: RNA
- BridgeBio Pharma Launches GondolaBio Joint Venture, from 8 hours ago by MT Newswires
  8 hours ago by MT Newswires
  Companies Mentioned: BBIO
Aug 19, 2024
- Avidity Biosciences Raises $345.1 Million From Upsized Public Offering, from 9:50AM ET on Monday Aug 19, 2024 by MT Newswires
  9:50AM ET on Monday Aug 19, 2024 by MT Newswires
  Companies Mentioned: RNA
- Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares, from 9:00AM ET on Monday Aug 19, 2024 by PR Newswire
  9:00AM ET on Monday Aug 19, 2024 by PR Newswire
  Companies Mentioned: RNA
- Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares, from 9:00AM ET on Monday Aug 19, 2024 by Dow Jones
  9:00AM ET on Monday Aug 19, 2024 by Dow Jones
  Companies Mentioned: RNA
- BridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia, from 7:30AM ET on Monday Aug 19, 2024 by GlobeNewswire
  7:30AM ET on Monday Aug 19, 2024 by GlobeNewswire
  Companies Mentioned: BBIO
- BridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia, from 7:30AM ET on Monday Aug 19, 2024 by Dow Jones
  7:30AM ET on Monday Aug 19, 2024 by Dow Jones
  Companies Mentioned: BBIO
Aug 15, 2024
- Avidity Biosciences Prices Stock Offering at $41 Per Share, from 3:40AM ET on Thursday Aug 15, 2024 by MT Newswires
  3:40AM ET on Thursday Aug 15, 2024 by MT Newswires
  Companies Mentioned: RNA
Aug 14, 2024
- *DJ Avidity Biosciences Prices Upsized Underwritten Public Offering of 7.32M Shares at $41.00 Each >RNA, from 9:22PM ET on Wednesday Aug 14, 2024 by Dow Jones
  9:22PM ET on Wednesday Aug 14, 2024 by Dow Jones
  Companies Mentioned: RNA

Madrigal Pharmaceuticals Inc
NASDAQ:MDGLUnited States

Search Criteria

Aug 8, 2024

DJ Madrigal Pharmaceuticals Is Maintained at Buy by Citigroup, from 3:32PM ET on Thursday Aug 08, 2024 by Dow Jones

DJ Madrigal Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group, from 9:19AM ET on Thursday Aug 08, 2024 by Dow Jones

B. Riley Adjusts Price Target on Madrigal Pharmaceuticals to $194 From $200, Maintains Neutral Rating, from 8:43AM ET on Thursday Aug 08, 2024 by MT Newswires

Aug 7, 2024

Madrigal Pharmaceuticals Reports Q2 Revenue as Loss Widens; Shares Gain Pre-Bell, from 8:14AM ET on Wednesday Aug 07, 2024 by MT Newswires

-- Earnings Flash (MDGL) MADRIGAL PHARMACEUTICALS Posts Q2 Loss $-7.10, vs. Street Est of $-7.61, from 7:07AM ET on Wednesday Aug 07, 2024 by MT Newswires

Peers Headlines

Today

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 7 hours ago by PR Newswire

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 7 hours ago by Dow Jones

BridgeBio Pharma Launches GondolaBio Joint Venture, from 8 hours ago by MT Newswires

Aug 19, 2024

Avidity Biosciences Raises $345.1 Million From Upsized Public Offering, from 9:50AM ET on Monday Aug 19, 2024 by MT Newswires

Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares, from 9:00AM ET on Monday Aug 19, 2024 by PR Newswire

Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares, from 9:00AM ET on Monday Aug 19, 2024 by Dow Jones

BridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia, from 7:30AM ET on Monday Aug 19, 2024 by GlobeNewswire

BridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia, from 7:30AM ET on Monday Aug 19, 2024 by Dow Jones

Aug 15, 2024

Avidity Biosciences Prices Stock Offering at $41 Per Share, from 3:40AM ET on Thursday Aug 15, 2024 by MT Newswires

Aug 14, 2024

*DJ Avidity Biosciences Prices Upsized Underwritten Public Offering of 7.32M Shares at $41.00 Each >RNA, from 9:22PM ET on Wednesday Aug 14, 2024 by Dow Jones